Schedule
New Patients Referring Physicians
Find a Doctor
Patient Portal
Log In Enroll
Careers
Locations
1-888-663-3488
English
English Spanish
Donate

Department Metrics

View the grants, clinical trials and publications from the Integrated Mathematical Oncology Department.

  • Grants

    • Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
      Award Number:
      Sponsor: Nat Institutes of Health
      PI (Contact):Rejniak, K.,PI (MPI):Pilon-Thomas, S.
    • Characterizing Cytotoxic Therapy Induced Shifts in the Cost-to-Benefit Ratio of High Ploidy
      Award Number:
      Sponsor: Nat Institutes of Health
      PI:Andor, N.
    • Development of Adoptive T-Cell Therapy in Bladder Cancer Incorporating Patient-Specific Tumor Microenvironment
      Award Number:
      Sponsor: US Army
      PI:Rejniak, K.
    • Modeling the Role and Regulation of Reactive Stroma in Breast Ductal Carcinoma Microinvasions
      Award Number:
      Sponsor: Nat Institutes of Health
      PI:Rejniak, K.
    • The Delta Ecology of NSCLC Treatment
      Award Number:
      Sponsor: Nat Institutes of Health
      PI (Contact):Anderson, A.,PI (MPI):Gatenby, R.,Project PI:Marusyk, A.
    • The Delta Ecology of NSCLC Treatment - Diversity Supplement
      Award Number:
      Sponsor: Nat Institutes of Health
      PI (Contact):Anderson, A.,PI (MPI):Gatenby, R.

  • Publications

    • Prabhakaran S, Gatenbee CD, Robertson-Tessi M, Gahramanli Ozturk Z, Boyle TA, Gray JE, Antonia SJ, Gatenby RA, Beg AA, Anderson ARA. Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response. Cancer Res. 2026 Mar.86(5):1269-1285. Pubmedid: 41418101. Pmcid: PMC12871056.
    • Luddy KA, West J, Robertson-Tessi M, Desai B, Ojeda A, Newman H, Estrella V, Bursell TM, Barrett S, O'Sullivan J, Marignol L, Gatenby RA, Brown JS, Anderson AR, O'Farrelly C. Evolutionary Double-Bind Treatment Using Radiation Therapy and Natural Killer Cell-Based Immunotherapy in Prostate Cancer. Int J Radiat Oncol Biol Phys. 2026 Mar.124(3):702-716. Pubmedid: 40998270. Pmcid: PMC12908384.
    • Marzban S, Stiehl T, Xie Z, Andersen M, Snyder J, Gudmand-Høyer J, Ottesen JT, Mon Père NV, Werner B, Huang W, DeZern AE, Sekeres MA, Walter MJ, Padron E, Gillis N, West J. Modeling the evolutionary dynamics of clonal hematopoiesis. Nat Genetics. 2026 Feb. Pubmedid: 41699138.
    • Rockne RC, Andersen M, Anderson ARA, Basanta D, Bentivegna A, Benzekry S, Branciamore S, Brüningk SC, Conte M, Farahpour F, Karolak A, Köhn-Luque A, Lorenzo G, Manookian B, Rodin AS, Schmalenstroer L, Soler J, Tomasetti C, Urbaniak K. The future of mathematical oncology in the age of AI. NPJ Syst Biol Appl. 2026 Jan.12(1):22. Pubmedid: 41588010. Pmcid: PMC12890909.
    • Pradelli F, Strobl M, Marzban S, de Kermenguy F, Barnett A, Ganesan K, Lorenzo G, Hormuth DA, Hamis S, Bhaskar D, Anderson ARA, West J. 75 Years of Mathematical Oncology. bioRxiv. 2026 Jan. Pubmedid: 41648173. Pmcid: PMC12871332.
    • Schneider K, Spekking L, Azimi S, Peltanová B, Rösel D, Brown JS, Gatenby RA, Brábek J, Staňková K. Migrastatic therapy as a potential game-changer in adaptive cancer treatment. Sci Rep. 2026 Jan.16(1):3929. Pubmedid: 41484230. Pmcid: PMC12855177.
    • Gevertz JL, Jain HV, Kareva I, Wilkie KP, Brown J, Huang YP, Sontag E, Vinogradov V, Davies M. Delaying cancer progression by integrating toxicity constraints in a model of adaptive therapy. NPJ Syst Biol Appl. 2026 Jan.12(1):11. Pubmedid: 41501069. Pmcid: PMC12820236.
    • Luddy K, Newman H, Gravon J, Robertson-Tessi M, Gatenby R. Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer. PET Clin. 2026 Jan.21(1):169-180. Pubmedid: 41136296.
    • Gravenmier C, Marzban S, Tang YH, Gillis N, Shah BD, Moscinski LC, Zhang L, West J. Cell State Transitions Drive the Evolution of Disease Progression in B-Lymphoblastic Leukemia. Cancer Res Commun. 2026 Jan.6(1):47-59. Pubmedid: 41295979. Pmcid: PMC12775648.
    • Bekker RA, Brady-Nicholls R, de Pillis L, Gevertz JL, Jain HV. Integrating machine learning into the in silico clinical trial pipeline. Math Biosci. 2026 Jan.391:109583. Pubmedid: 41308950.
    • Olumoyin KD, Park M, Davis EW, Permuth JB, Rejniak KA. Machine Learning-Based Identification of Blood Biomarkers that Distinguish Precachectic and Cachectic Patients with Pancreatic Ductal Adenocarcinoma. medRxiv. 2025 Dec. Pubmedid: 41480031. Pmcid: PMC12755264.
    • Park MA, Davis EW, Alhassan S, Arnoletti JP, Basinski TL, McKee AB, Bloomston M, Carson TL, Biachi de Castria T, Chen DT, Cortizas EM, Crowder SL, Delgado MG, Douglas WG, Fleming JB, Hodul P, Huguet KL, Jiang K, Kim DW, Koomen J, Luthra AK, Malafa M, Menon AA, Morales R, Merchant NB, Meredith K, Mo Q, Molina-Vega MA, Moreno-Urazan L, Olumoyin KD, Parker N, Pimiento JM, Rasool G, Rejniak KA, Sansil S, Sparks LM, Stewart P, Tassielli AF, Teer JK, Tran DV, Trevino JG, Velanovich V, Whelan CJ, Jeong D, Judge SM, Judge AR, Permuth JB. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Commun Med (Lond). 2025 Dec.6(1):19. Pubmedid: 41413302. Pmcid: PMC12789063.
    • Olumoyin K, El Naqa L, Rejniak K. Learning Model Parameter Dynamics in a Combination Therapy for Bladder Cancer from Sparse Biological Data. ArXiv. 2025 Dec. Pubmedid: 41445818. Pmcid: PMC12723788.
    • Beck RJ, Li T, Andor N. ALFA-K: Local adaptive mapping of karyotype fitness landscapes. Nat Commun. 2025 Dec.17(1):1015. Pubmedid: 41455703. Pmcid: PMC12848095.
    • Pergams A, Haus M, Estrada C, Brown J, Salles A. Dinner Date: Opposite-Sex Pairs of Fruit Bats (Rousettus aegyptiacus) Forage More than Same-Sex Pairs. Biology (Basel). 2025 Dec.14(12). Pubmedid: 41463515. Pmcid: PMC12730429.
    • Scibilia KR, Gallagher K, Masud MA, Robertson-Tessi M, Gatenbee CD, West J, Llamas P, Prabhakaran S, Gallaher J, Anderson ARA. Mathematical Oncology: How Modeling Is Transforming Clinical Decision-Making. Cancer Res. 2025 Dec.85(24):4866-4879. Pubmedid: 41105675. Pmcid: PMC12614879.
    • Gatenby RA, Anderson ARA, Brown JS, Gallaher J, Krolick J, Lemanne D. Directed Evolution Restored Castrate Sensitivity in a Patient With Castrate Resistant Metastatic Prostate Cancer. Prostate. 2025 Dec.85(16):1562-1567. Pubmedid: 40878050.
    • Obertopp N, Froid M, Pilon-Thomas S, Basanta D. Rethinking the seven-day treatment-free interval in T-cell engager therapy using agent-based modeling. bioRxiv. 2025 Nov. Pubmedid: 41332775. Pmcid: PMC12667981.
    • Beck R, Tagal V, Amin S, Bakhoum SF, Maley C, Verhaak RGW, Gomes AP, Andor N. Energetics of whole genome doubling and genomic instability. Cancer Lett. 2025 Oct.630:217878. Pubmedid: 40517938.
    • Olumoyin K, Rejniak K. Modeling Adoptive Cell Therapy in Bladder Cancer from Sparse Biological Data using PINNs. ArXiv. 2025 Oct. Pubmedid: 41281226. Pmcid: PMC12633144.
    • Hosny N, Shen K, Zhao Y, Qu J, Sun Y, Butler G, Amend S, Hammarlund EU, Gatenby R, Brown J, Pienta KJ, Phan TV, Boyer-Paulet S, Li S, Austin RH. Protocol to model tumor hypoxia in vitro using real-time phosphorescence-based sensing of O2 gradients generated by metastatic cancer cells. STAR Protoc. 2025 Oct.6(4):104163. Pubmedid: 41150854. Pmcid: PMC12597275.
    • Gallagher K, Strobl MAR, Anderson ARA, Maini PK. Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics. Bull Math Biol. 2025 Sep.87(10):146. Pubmedid: 40921859. Pmcid: PMC12417256.
    • Arabzadeh M, Tang YH, Colin-Leitzinger C, Marzban S, Walgenbach D, Morganti S, Mahaganapathy V, Harper E, Teng M, Kresovich JK, Washington I, Parsons HA, Garber JE, West J, Ganesan S, Khiabanian H, Gillis N. Clonal Hematopoiesis Dynamics and Evolutionary Fitness During Cancer Treatment Impact Clinical Outcomes. medRxiv. 2025 Sep. Pubmedid: 40950448. Pmcid: PMC12424905.
    • West J, Desai B, Strobl M, Gallaher J, Robertson-Tessi M, Marusyk A, Anderson ARA. Evolutionary antifragile therapy. bioRxiv. 2025 Sep. Pubmedid: 41000654. Pmcid: PMC12458151.
    • Milne A, Marusyk A, Maini PK, Anderson ARA, Picco N. The role of environmentally mediated drug resistance in facilitating the spatial distribution of residual disease. Commun Biol. 2025 Aug.8(1):1189. Pubmedid: 40783466. Pmcid: PMC12335614.
    • Tyczynska Weh M, Kumar P, Marusyk V, Marusyk A, Basanta D. The adaptive state determines the impact of mutations on evolving populations. Proc Natl Acad Sci U S A. 2025 Jul.122(26). Pubmedid: 40569384. Pmcid: PMC12232665.
    • Veith T, Beck R, Tagal V, Li T, Alahmari S, Cole J, Hannaby D, Kyei J, Yu X, Maksin K, Schultz A, Lee H, El Naqa I, Eschrich S, Ji HP, Diaz A, Andor N. CLONEID: A Framework for Longitudinal Integration of Phenotypic and Genotypic Data to Monitor and Steer Subclonal Dynamics. bioRxiv. 2025 Jul. Pubmedid: 40631300. Pmcid: PMC12236826.
    • Beck RJ, Andor N. Local Adaptive Mapping of Karyotype Fitness Landscapes. bioRxiv. 2025 Jun. Pubmedid: 40667108. Pmcid: PMC12262491.
    • Chamseddine I, Kambara M, Bhatt P, Pilon-Thomas S, Rejniak KA. Optimizing the Efficacy of Vaccine-Induced Immunotherapy in Melanomas. Bull Math Biol. 2025 May.87(7):86. Pubmedid: 40434675. Pmcid: PMC12279038.
    • Hosny N, Shen K, Zhao Y, Qu J, Sun Y, Butler G, Amend S, Hammarlund EU, Gatenby R, Brown J, Pienta KJ, Phan TV, Boyer-Paulet S, Li S, Austin RH. Phosphorescence-based sensing reveals size-dependent survival and motility of metastatic prostate cancer cells in self-generated hypoxia. iScience. 2025 May.28(5):112325. Pubmedid: 40475852. Pmcid: PMC12139443.
    • Gatenby RA, Teer JK, Tsai KY, Brown JS. Parallel and convergent dynamics in the evolution of primary breast and lung adenocarcinomas. Commun Biol. 2025 May.8(1):775. Pubmedid: 40399443. Pmcid: PMC12095661.
    • Gallagher K, Strobl MAR, Anderson ARA, Maini PK. Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics. medRxiv. 2025 Apr. Pubmedid: 40236415. Pmcid: PMC11998818.
    • Desai B, Miti T, Prabhakaran S, Miroshnychenko D, Henry M, Marusyk V, Kumar P, Ozakinci H, Gatenbee C, Bui M, Boyle TA, Scott J, Altrock PM, Haura E, Anderson ARA, Basanta D, Marusyk A. Multifactorial stroma-mediated resistance is a major contributor to residual disease under targeted therapies in lung cancers. Res Sq. 2025 Apr. Pubmedid: 40313737. Pmcid: PMC12045365.
    • Nowicka Z, Rentzeperis F, Tagal V, Teer JK, Ilter D, Beck RJ, Cole JP, Forero Pinto AM, Tejero JD, Scanu E, Veith T, Dominguez-Viqueira W, Maksin K, Carrillo-Perez FM, Gevaert O, Xu X, Karreth FA, Abdalah MA, Fiandaca G, Pasetto S, Prabhakaran S, Schultz A, Ojwang' AME, Barnholtz-Sloan JS, Farinhas JM, Gomes AP, Katira P, Andor N. Interactions between Ploidy and Resource Availability Shape Clonal Evolution in Glioblastoma. Cancer Res. 2025 Apr.85(8):1544-1559. Pubmedid: 39933186.
    • Bhattacharya R, Avdieiev SS, Bukkuri A, Whelan CJ, Gatenby RA, Tsai KY, Brown JS. The Hallmarks of Cancer as Eco-Evolutionary Processes. Cancer Discov. 2025 Apr.15(4):685-701. Pubmedid: 40170539.
    • Hammarlund EU, Bukkuri A, Norling MD, Islam M, Posth NR, Baratchart E, Carroll C, Amend SR, Gatenby RA, Pienta KJ, Brown JS, Peters SE, Hancke K. Benthic diel oxygen variability and stress as potential drivers for animal diversification in the Neoproterozoic-Palaeozoic. Nat Commun. 2025 Mar.16(1):2223. Pubmedid: 40118825. Pmcid: PMC11928486.
    • Park MA, Whelan CJ, Ahmed S, Boeringer T, Brown J, Carson TL, Crowder SL, Gage K, Gregg C, Jeong DK, Jim HSL, Judge AR, Mason TM, Parker N, Pillai S, Qayyum A, Rajasekhara S, Rasool G, Tinsley SM, Schabath MB, Stewart P, West J, McDonald P, Permuth JB. Correction: Park et al. Defining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration. Cancers 2024, 16, 2364. Cancers (Basel). 2025 Mar.17(6). Pubmedid: 40149388. Pmcid: PMC11941415.
    • Veith T, Beck R, Brown JS, Andor N. Inverse Game Theory Characterizes Frequency-Dependent Selection Driven by Karyotypic Diversity in Triple Negative Breast Cancer. bioRxiv. 2025 Mar. Pubmedid: 40196548. Pmcid: PMC11974723.

Cambiar el idioma

Si no encuentra la información que busca o si desea programar una cita, llámenos gratis al 1-888-663-3488.

Gracias.

 

 

 

 

Cancel | Cancelar OK